AlzChem Group AG: Synthetically produced creatine can alleviate creatine deficiency syndrome

Dow Jones received a payment from EQS/DGAP to publish this press release.

DGAP-Media / 2018-09-13 / 16:16 
 
*Synthetically produced creatine can alleviate creatine deficiency syndrome* 
 
At the first creatine deficiency syndrome (CCDS) symposium in Austin, Texas, 
which AlzChem sponsored, several patients reported positive treatment 
outcomes with creatine. Creatine is an endogenous substance produced in the 
liver and kidneys and is essential for energy supply to the brain, muscles 
and immune system. In people with creatine deficiency syndrome (Cerebral 
Creatine Deficiency Syndrome, CCDS), the body's creatine metabolism does not 
function properly, to word it simply, so that the brain is not supplied with 
creatine. "This disorder is congenital and has various manifestations. The 
body is either unable to produce creatine or to transport it to the cells. 
The consequences are often serious: children with CCDS suffer from mental 
and physical developmental disorders, and are usually unable to walk or 
speak, often suffering from epilepsy, autism or mental disabilities," 
explains Dr. Ulrike Braun, Product Manager at AlzChem and symposium 
participant. 
 
Organized by the Association for Creatine Deficiencies (ACD), the event 
aimed to bring affected people worldwide together for the first time to 
promote exchange among each other and with experts from science and 
industry. The association's work was also able to be communicated to 
patients: to raise awareness of this disease, emphasize the importance of 
describing the course of the disease for physicians and scientists, and 
illustrate early diagnosis and treatment efforts. Creatine deficiency 
diseases are often not recognized until late because it is a rare disease 
without clearly standardized diagnostic methods and not often covered by 
insurance, making it expensive. Early detection, ideally in newborns, and 
appropriate therapy can alleviate the symptoms and significantly improve 
children's quality of life. ACD is therefore committed to including CCDS in 
general newborn screening. 
 
"We estimate that approximately 500 CCDS cases have been diagnosed 
worldwide. The actual number of people affected is likely to be 
significantly higher, however, as the disorder is usually only found when 
specifically looked for," reports Kim Tuminello, Co-Founder and Director of 
Advocacy. In some of these cases, creatine as a dietary supplement can 
partially or even completely compensate for the deficit - depending on the 
age of the affected person - so that the patients develop completely 
normally. "Creatine is an essential source of energy for every cell in the 
body. The severity of creatine deficiency diseases illustrates the central 
importance of creatine for the organism as well as for physical and mental 
development. I am very proud that our product can help here," says Dr. 
Ulrike Braun. 
 
*Creatine from AlzChem* 
Under the brand name Creapure(R), AlzChem offers a dietary supplement 
consisting of the body's own substance creatine, which helps build muscle 
and increase physical performance. AlzChem produces the pure creatine 
monohydrate in Germany according to strict guidelines in food and 
pharmaceutical quality with every batch thoroughly tested for purity. 
The European Food Safety Authority (EFSA) has confirmed the positive effects 
of creatine as a dietary supplement for athletes as well as for people over 
55 years of age who exercise and strength train regularly. 
 
*About AlzChem Group AG* 
AlzChem Group AG is a vertically integrated manufacturer of various chemical 
products based on the NCN chain. These are products with typical 
nitrogen-carbon-nitrogen bonding that are used in a wide variety of 
different industries. The company has a leading position in select niche 
markets. The strategic focus of growth and the main focus of its extensive 
research and development are on the business segment Specialty Chemicals. 
The company has around 1,500 employees at four sites in Germany and three 
other sites abroad. 
 
End of Media Release 
 
Issuer: AlzChem Group AG 
Key word(s): Research/Technology 
 
2018-09-13 Dissemination of a Press Release, transmitted by DGAP - a service 
of EQS Group AG. 
The issuer is solely responsible for the content of this announcement. 
 
The DGAP Distribution Services include Regulatory Announcements, 
Financial/Corporate News and Press Releases. 
Archive at www.dgap.de 
Language: English 
Company:  AlzChem Group AG 
          Dr.-Albert-Frank-Str. 32 
          83308 Trostberg 
          Germany 
Phone:    [phone] 
Fax:      [phone] 
E-mail:   [e-mail] 
Internet: www.alzchem.com 
ISIN:     DE000A0AHT46 
WKN:      A0AHT4 
Listed:   Regulated Market in Frankfurt (Prime Standard); Regulated 
          Unofficial Market in Stuttgart 
 
End of News DGAP Media 
 
723451 2018-09-13 
 
 

(END) Dow Jones Newswires

September 13, 2018 10:16 ET (14:16 GMT)